Compare FOR & CTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOR | CTY |
|---|---|---|
| Founded | 2005 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2007 | 2026 |
| Metric | FOR | CTY |
|---|---|---|
| Price | $24.02 | $18.54 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $34.00 | N/A |
| AVG Volume (30 Days) | 177.3K | ★ 214.1K |
| Earning Date | 10-29-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $1,662,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | $14.75 | ★ N/A |
| Revenue Growth | ★ 10.14 | N/A |
| 52 Week Low | $22.81 | $15.81 |
| 52 Week High | $32.06 | $22.65 |
| Indicator | FOR | CTY |
|---|---|---|
| Relative Strength Index (RSI) | 41.24 | 38.35 |
| Support Level | N/A | $15.81 |
| Resistance Level | $26.36 | $22.65 |
| Average True Range (ATR) | 0.92 | 1.70 |
| MACD | -0.09 | -0.34 |
| Stochastic Oscillator | 17.46 | 39.91 |
Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. The company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.
City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.